EchoNous Launches Continuous and Pulsed Wave Doppler on Kosmos Hand-Carried Hardware

EchoNous, developers of AI-driven, hand-carried ultrasound, today announced the addition of both continuous wave (CW) and pulsed wave (PW) Doppler capabilities to the Kosmos hardware platform, the company’s flagship offering.

This innovation represents an industry first for an ultra-mobile, ultrasound product; creating the first “hybrid” point-of-care ultrasound (POCUS) device, offering large machine-benchmarked ultrasound imaging and Doppler functionality in a hand-carried unit (HCU).

Designed as an all-in-one diagnostic tool that can be carried from bedside to bedside, Kosmos was developed with the essential technology necessary for highly sensitive CW and PW wave Doppler scanning already built-in notes EchoNous.

Kosmos units are now easily upgradeable over the air for the addition of CW and PW Doppler.

The inclusion of these tools rounds out Kosmos’s already comprehensive suite of diagnostic capabilities. This suite includes AI-assisted systolic heart function, which is derived from high-resolution imaging and enabled by a novel new algorithmic tool, ‘Trio.’

Prior to this launch, CW Doppler had historically eluded the HCU POCUS market. Kosmos’s hybrid approach is designed from the ground up based on specifications historically found on more expensive cart-based models.

Benchmarks include greater power, a high signal-to-noise ratio, and an increased channel count (64 channels). These features are all essential for high performance with increased sensitivity CW Doppler.

“We firmly believe that POCUS is the future of medicine and that HCU must be delivered on par with larger, more expensive machines – our tools should not be limited by their size,” explained Kevin Goodwin, CEO of EchoNous. “By removing these hurdles, we now offer diagnostic-grade capabilities to answer specific clinical questions for cardiologists and all clinician users; focused on upgrading bedside medicine with higher-performance tools that remain less expensive.”

SourceEchoNous

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”